Literature DB >> 1964059

Feline immunodeficiency virus (FIV) infection in the cat as a model for HIV infection in man: FIV-induced impairment of immune function.

K H Siebelink1, I H Chu, G F Rimmelzwaan, K Weijer, R van Herwijnen, P Knell, H F Egberink, M L Bosch, A D Osterhaus.   

Abstract

To assess the value of feline immunodeficiency virus (FIV) infection as a model for human immunodeficiency virus (HIV) infection in man, we studied the impairment of certain immunological functions following natural or experimental FIV infection. Proliferative responses of peripheral blood mononuclear cells (PBMC) from symptomatic and asymptomatic cats after naturally or experimentally acquired FIV infection, induced by activation with the mitogens concanavalin A, pokeweed mitogen, or lipopolysaccharide or by stimulation with human interleukin-2 (IL-2), were significantly lower than the proliferative responses found with PBMC from noninfected control cats. Also IL-2 production levels of mitogen-activated PBMC from naturally infected symptomatic cats were significantly reduced. These data confirm that the pathogenesis of FIV infection in the cat, like HIV infection in man, is characterized by a serious malfunction of the immune system.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1964059     DOI: 10.1089/aid.1990.6.1373

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN: 0889-2229            Impact factor:   2.205


  30 in total

1.  Prevention of immunodeficiency virus induced CD4+ T-cell depletion by prior infection with a non-pathogenic virus.

Authors:  Julie A Terwee; Jennifer K Carlson; Wendy S Sprague; Kerry S Sondgeroth; Sarah B Shropshire; Jennifer L Troyer; Sue VandeWoude
Journal:  Virology       Date:  2008-05-22       Impact factor: 3.616

Review 2.  Feline immunodeficiency virus model for designing HIV/AIDS vaccines.

Authors:  Janet K Yamamoto; Missa P Sanou; Jeffrey R Abbott; James K Coleman
Journal:  Curr HIV Res       Date:  2010-01       Impact factor: 1.581

3.  Neutralization of feline immunodeficiency virus by polyclonal feline antibody: simultaneous involvement of hypervariable regions 4 and 5 of the surface glycoprotein.

Authors:  K H Siebelink; W Huisman; J A Karlas; G F Rimmelzwaan; M L Bosch; A D Osterhaus
Journal:  J Virol       Date:  1995-08       Impact factor: 5.103

4.  Isolation of a highly cytopathic lentivirus from a nondomestic cat.

Authors:  M C Barr; L Zou; D L Holzschu; L Phillips; F W Scott; J W Casey; R J Avery
Journal:  J Virol       Date:  1995-11       Impact factor: 5.103

5.  A single amino acid substitution in hypervariable region 5 of the envelope protein of feline immunodeficiency virus allows escape from virus neutralization.

Authors:  K H Siebelink; G F Rimmelzwaan; M L Bosch; R H Meloen; A D Osterhaus
Journal:  J Virol       Date:  1993-04       Impact factor: 5.103

Review 6.  Feline immunodeficiency virus: an interesting model for AIDS studies and an important cat pathogen.

Authors:  M Bendinelli; M Pistello; S Lombardi; A Poli; C Garzelli; D Matteucci; L Ceccherini-Nelli; G Malvaldi; F Tozzini
Journal:  Clin Microbiol Rev       Date:  1995-01       Impact factor: 26.132

7.  Cytokine production by cats infected with feline immunodeficiency virus: a longitudinal study.

Authors:  C E Lawrence; J J Callanan; B J Willett; O Jarrett
Journal:  Immunology       Date:  1995-08       Impact factor: 7.397

8.  Feline immunodeficiency virus predisposes cats to acute generalized toxoplasmosis.

Authors:  M G Davidson; J B Rottman; R V English; M R Lappin; M B Tompkins
Journal:  Am J Pathol       Date:  1993-11       Impact factor: 4.307

Review 9.  Immunopathogenesis of feline immunodeficiency virus infection in the fetal and neonatal cat.

Authors:  Holly M Kolenda-Roberts; Leah A Kuhnt; Ryan N Jennings; Ayalew Mergia; Nazareth Gengozian; Calvin M Johnson
Journal:  Front Biosci       Date:  2007-05-01

10.  Induction of feline immunodeficiency virus-specific cytolytic T-cell responses from experimentally infected cats.

Authors:  W Song; E W Collisson; P M Billingsley; W C Brown
Journal:  J Virol       Date:  1992-09       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.